50 results about "Acute ischemia" patented technology

The invention relates to 4 serum peptide patterns for diagnostics of intracranial hemorrhagic stroke (ICH) in humans and differential diagnosis from acute ischemic stroke that are defined using a list of the 34 quantitative peptides that in sera of patients with ICH are increased 2 folds or more as compared with individuals without stroke and patients with acute ischemic stroke and a list of 16 qualitative peptides detectable in sera of the patients with ICH but not detectable in the sera of individuals without stroke and in sera of patients with acute ischemic stroke.

The invention belongs to the technical field of biological medicine. More specifically, the invention provides the annular RNACircMAP2, and the sequence of the annular RNACircMAP2 is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. The invention proves that CircMAP2 can be used as a novel biomarker for diagnosing acute ischemic stroke for the first time. Compared with a traditional imaging diagnosis method, the acute ischemic stroke can be diagnosed by detecting the expression level of the CircMAP2 in the plasma and the plasma exosome of the patient, the cerebral infarction area of the acute ischemic stroke can be speculated through the expression level of the CircMAP2, and the method has the advantages of being easy and convenient to operate, high in detection speed and low in cost; the system is especially suitable for popularization and use in primary medical institutions. The product for diagnosing acute ischemic stroke provided by the invention can quickly and accurately diagnose acute ischemic stroke, and has good clinical popularization prospect and application value.

In MRI examinations of patients with acute ischemic stroke, it is often difficult for patients to fix and hold their heads due to impaired consciousness or limb weakness. Therefore, this invention provides a tool that is structurally rational, easy to operate, and effectively enhances the head fixation effect. [Solution] A tool to support MRI examination, comprising a base 1, a head rest member 2 with adjustable anterior-posterior position, a lateral limiting member 3 with an elastic buffer layer, and an adjustment mechanism 4. The head rest member slides relative to the base to adapt to the length of the patient's neck. The lateral limiting member is biased inward by a compression coil spring and flexibly holds both sides of the head with an elastic buffer layer, absorbing and suppressing involuntary movements. The adjustment mechanism uses a single reverse-threaded adjustment rod to synchronously and symmetrically move the left and right limiting plates, enabling precise adjustment according to the head circumference. This effectively limits multi-directional micro-movements of the head during imaging and improves image stability.

Compositions comprising Lumbricus terrestris erythrocruorin (LtEc) as an oxygen carrier for use in transfusion and organ perfusion are provided. In particular, methods of using acellular compositions comprising LtEc as a universal blood substitute for transfusion of patients are provided. The methods also include ex vivo perfusion of an organ or tissue with an oxygenated acellular perfusate comprising LtEc as an oxygen carrier. Additionally, methods are provided for using compositions comprising LtEc in treatment of acute ischemia and hyperbaric oxygen therapy.

The present invention is directed to a method of treating acute ischemic stroke in a human comprising administering one of more low doses of DC009, wherein the dose is about 0.01-0.075 mg / kg / dose. The low dose administration is safe and effective in treating acute ischemic stroke in a human subject.

The invention belongs to the technical field of biology, and particularly relates to application of Lnc-PLBD1-AS1 and MCEMP1 as prognosis biomarkers of acute ischemic stroke. According to the application disclosed by the invention, it is found that the expression levels of baseline Lnc-PLBD1-AS1 and MCEMP1 of people who are dead within one year after an acute cerebral arterial thrombosis patient is attacked are obviously higher than those of survival patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of death of the acute cerebral arterial thrombosis patient within one year after the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient; the expression levels of the baselines Lnc-PLBD1-AS1 and MCEMP1 of people suffering from the adverse function outcome (death or severe disability) of acute cerebral arterial thrombosis patients after attack for 3 months are obviously higher than those of other patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of the adverse function outcome of the acute cerebral arterial thrombosis patients after attack for 3 months.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

Disclosed in the present invention is a pharmaceutical composition, comprising anisodine or a salt thereof and 2-borneol or a related substance thereof. The pharmaceutical composition provided in the present invention exhibits synergistic effects in the treatment of cardiovascular and cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, and can effectively improve outcomes of patients with cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, thereby enhancing the quality of life of the patients.

The invention relates to the technical field of biology, in particular to a method for modular assembly of artery blood vessel type organs and construction of tissue microcirculation of the artery blood vessel type organs. The method comprises the following steps: inducing human pluripotent stem cells to differentiate through a mesoderm stage to form an arterial specific vascular organoid module (AVO), and then carrying out modular assembly on the AVO in vivo or in vitro so as to quickly reconstruct a tissue microcirculation network with arterial characteristics. The obtained artery blood vessel organoid is uniform in form, the diameter of the artery blood vessel organoid is intensively distributed at about 200 microns, SOX17 and CXCR4 artery endothelial markers are expressed at the same time, and the artery blood vessel organoid has polarity and a complete basilar membrane. Transplanting experiments show that the organ can be integrated with host blood vessels in a short time, and ischemic tissue blood perfusion is recovered. The defects that existing organoid is irregular, difficult to splice, delayed in perfusion and the like are overcome, and a new strategy is provided for revascularization and acute ischemic disease repair.

A metal medicine expansion balloon without blocking blood flow comprises an adjustable inner conveying system and a screw-in type outer conveying system, the adjustable inner conveying system is formed by connecting a supporting balloon with an adjustable handle through an inner pushing rod, the screw-in type outer conveying system is arranged on the periphery of the adjustable inner conveying system, and the screw-in type outer conveying system is connected with the adjustable handle through an outer pushing rod. Comprising a covered stent, a drug coating film, a main body skeleton, an outer pushing rod and a screw-in valve, the drug coating film covers the main body skeleton through the covered stent, the near end of the covered stent is connected with the far end of the outer pushing rod, and the near end of the outer pushing rod is connected with the far end of the screw-in valve. The internal system and the external system work cooperatively, a multi-channel blood flow path is formed during expansion, intraoperative blood perfusion is kept, acute ischemia and thrombosis risks during the operation are reduced, the internal supporting balloon adopts a shape memory alloy weaving process, pressure feedback in the expansion process is more obvious, the adherence gap is smaller, the adherence process is conformal, and the system is more suitable for complex lesions; meanwhile, the cutting effect is achieved, and the expansion effect is effectively improved.

The application discloses application of a 2-amino-pyrazine derivative in preparation of a medicine for treating and / or preventing apoplexy and complications, wherein the 2-amino-pyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl]oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,6-dimethylbenzamide; the apoplexy is acute ischemic stroke; and the 2-amino-pyrazine derivative can be used as an active ingredient in a medicine for treating and / or preventing post-stroke brain injury and complications, effectively reducing post-stroke cerebral infarction volume, improving sensory-motor and balance nerve functions, and preventing and treating post-stroke complications such as cerebral edema and acute lung injury.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

A protein marker panel for screening clinical futile recanalization (FR) in patients with large vessel occlusion-induced acute ischemic stroke (LVO-AIS) and use thereof are provided. The protein marker panel includes GUCA2A, CCL14, STAB1, and VSIG4. A combined diagnostic value of the protein marker panel is high, and receiver operating characteristic (ROC) curve analysis demonstrates an efficacy in distinguishing and screening FR patients, with an area under the curve (AUC) of 0.959, indicating desirable sensitivity and specificity. Such a protein marker panel shows promise as a significant indicator for clinical decision-making in FR evaluation.

The application discloses an acute ischemic stroke prognosis prediction method based on CTA images, relates to the technical field of medical image processing, and fuses a three-dimensional visual transformer and a meta-learning strategy to train a target prognosis prediction model based on the three-dimensional visual transformer and matched with a target data acquisition condition.The target prognosis prediction model can effectively model a spatial dependence relationship in a three-dimensional CTA image across regions and layers, significantly improves the recognition ability of complex cerebral vascular structures and ischemic regions compared with a traditional convolution network which only depends on a local receptive field, and further more, the introduction of the meta-learning strategy can improve the model generalization ability under small samples and multiple data acquisition conditions, so that the target prognosis prediction model directly takes the CTA image to be predicted as input to realize automatic prognosis prediction, does not need manual segmentation or feature extraction, avoids the dependence on manual experience in the traditional method, and improves the standardization degree and repeatability of the model application.

The present application relates to the field of medicine, and discloses an integrated emergency stroke unit having regions. The integrated emergency stroke unit having regions comprises an information interaction area, an imaging examination area, and a thrombolysis treatment area. The information interaction area is provided with a doctor workstation, a comprehensive information monitoring display, and a process-support AI assistant. The imaging examination area is provided with a detection device, a first television display screen, a low-field movable magnetic resonance imager, and an AI-assisted decision-making system. The process-support AI assistant performs automated consultation and assists in nervous system scale scoring by means of voice interaction or touch screen input interaction, and also provides retrieval support for a real-time knowledge base and clinical guidelines. The AI-assisted decision-making system assists in decision-making on the basis of an automated consultation result, a scale scoring result, a detection result, and a head and neck magnetic resonance imaging result, generates a treatment plan, and displays the treatment plan. According to the present application, all diagnosis and treatment activities involved upon the arrival of a patient suffering from acute ischemic stroke at a hospital are integrated into a single space, which can significantly shorten diagnosis and treatment time.

This invention relates to novel 2-(1-hydroxypentyl)benzoate, its preparation method, and its applications. Specifically, it relates to a cycloalkanamine 2-(1-hydroxypentyl)benzoate with the structure shown in Formula I, its preparation method, pharmaceutical compositions with the compound as the active ingredient, and the application of the compound in the treatment and / or prevention of ischemic cardiovascular and cerebrovascular diseases, especially mild, moderate, and severe acute ischemic stroke.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

The invention relates to the technical field of deep learning, and discloses an acute ischemic stroke function outcome prediction method and device based on deep learning. The method comprises the following steps: segmenting a preprocessed stroke lesion image sequence and a preprocessed deep marrow vein image sequence by using a deep learning image segmentation model; generating a first image sequence according to the preprocessed stroke lesion image sequence and the lesion segmentation mask sequence; generating a second image sequence according to the preprocessed deep marrow vein image sequence and the deep marrow vein segmentation mask sequence; processing the first image sequence and the second image sequence by using a deep learning classification model to obtain a first functional result prediction result and a second functional result prediction result; and generating a stroke functional result prediction result based on the first functional result prediction result and the second functional result prediction result. According to the invention, the stroke function outcome can be predicted more quickly and accurately.

The invention relates to a polypeptide of SEQ ID NO: 1 for use in the treatment of acute ischaemic stroke (AIS) or in the prevention of the complications of AIS in an adult mammalian subject. The polypeptide can be used in patients in whom AIS is followed by reperfusion of ischemic brain tissue, or in patients in whom AIS is not followed by reperfusion of ischemic brain tissue (patients with permanent cerebral ischemia).

The present application relates to a kind of thrombus compression extraction device, by the way of vascular intervention is transported to embolism site and works.This device is made of thrombus blocking component, thrombus compression component and thrombus suction component;Thrombus compression component includes delivery catheter and thrombus compression balloon, thrombus compression balloon is fixed at the distal end of delivery catheter, the expansion and contraction degree of thrombus compression balloon is controllable;Thrombus suction component is tubular structure, delivery catheter can be relatively moved in the lumen of thrombus suction component, thrombus compression balloon can be retracted into the lumen of thrombus suction component with delivery catheter when in the contraction state.This device uses the mechanical property that stress will be greatly reduced when thrombus is compressed and keeps compression for a period of time, and uses thrombus compression balloon to compress thrombus and make it stress relaxation.Through thrombus suction component, thrombus can be helped to move out of body.The thrombus compression extraction device is convenient to use, makes thrombus more easily be sucked and taken out, is favorable to improve the success rate of taking out thrombus, reduces the side effect of sucking and taking out thrombus, and improves the treatment effect of acute ischemic stroke large vessel occlusion.

The application discloses an acute ischemic stroke perfusion image generation system based on non-contrast enhancement multi-modal images, which comprises four parts, an information acquisition module, a pretreatment module, an image generation module and a model evaluation module; the information acquisition module is used for collecting data information of patients to be diagnosed; the pretreatment module is used for standardizing and pretreating multi-modal images, that is, all images are processed through a standardized automatic pretreatment process; the image generation module is used for generating clinically available perfusion Tmax images by using a constructed adversarial generation network; and the model evaluation module is used for completing accurate segmentation and quantitative evaluation of key low perfusion areas by using a pre-trained segmentation network. The system disclosed by the application effectively expands the clinical application range of perfusion Tmax images, reduces medical costs, and reduces model deviation, so that the system can maintain stable performance on different devices and different population data.

This invention discloses a method for determining collateral circulation indicators based on single-phase CTA, including acquiring single-phase CTA images and DWI images; preprocessing the images to obtain first images at different levels; registering and identifying the blood-supplying brain tissue regions in the first images at different levels to obtain second images at different levels; identifying the ischemic foci area as the vascular aggregation area based on the DWI images, and mapping the vascular aggregation area to the second images at different levels to obtain third images at different levels; calculating the ratio of the area of ​​the vascular aggregation circle to the area of ​​the healthy side vascular circle in the third images at different levels; calculating the mean value based on the ratio and the number of third images, and determining it as the collateral circulation indicator value of the single-phase CTA image to obtain an intuitive and accurate assessment result. This method can be applied to the field of collateral circulation assessment in acute ischemic stroke based on single-phase CTA.

The invention relates to application of an MMP-7 inhibitor to treatment of acute ischemic stroke diseases, and belongs to the technical field of biological medicines, and the MMP-7 inhibitor is 7-hydroxy-6, 8-dimethoxybenzopyran-2-one (isofraxidin). The invention discloses the application of the MMP-7 inhibitor isofraxidin in improvement and treatment of the acute ischemic stroke for the first time, and experiments prove that the cerebral infarction area, nerve cell injury and brain cell apoptosis of the acute ischemic stroke can be remarkably reduced by giving the isofraxidin. Experimental results show that Isofraxidin has an obvious improvement effect on acute ischemic stroke, and has important significance on prevention and treatment of acute ischemic stroke clinically.

The invention is suitable for the technical field of hemorrhage risk prediction, and provides a model construction method based on an acute ischemic stroke hemorrhage transformation risk column diagram, and the method comprises the steps: firstly obtaining the characteristic variable data set information of a target patient, and then obtaining the characteristic variable data set information of the target patient based on the preset numerical value association set information; the feature score information corresponding to each piece of feature variable data information is quickly determined, and finally the bleeding transformation risk assessment information is accurately generated according to the plurality of pieces of feature score information. According to the method, the high-risk individuals suffering from hypertension can be identified through the column diagram, technical help is simply and visually provided for clinical decisions of clinicians, the accuracy and efficiency of the clinical decisions are improved, and improvement of the clinical treatment decisions of the high-risk patients suffering from bleeding is facilitated.

The invention provides an application of a marker group and / or a reagent for detecting the marker group in preparation of a product for predicting the functional outcome of acute ischemic stroke, the marker group comprises Parabacteroides, Oscillospira, Morganella, Dialister, Acidococcus, Enterobacter, Bifidobacterium, Megasphaera and Enterococcus, and the reagent for detecting the marker group can be used for detecting the functional outcome of acute ischemic stroke, and the marker group can be used for detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke and / or detecting the functional outcome of acute ischemic stroke. The invention discloses a marker group for detecting AIS (Automatic Identification System), which comprises any one or more of Pseudomonas, Streptococcus, Butyrimonas, Odobacter, Coprococcus and Roseburia microorganisms, the marker group further comprises a blood coagulation marker, and the marker group or a reagent for detecting the marker group provided by the invention can be used for better predicting the adverse function outcome of AIS patients, and can be used for detecting the adverse function outcome of the AIS patients. The method has good sensitivity and specificity, and a new efficient and accurate prediction means is provided for predicting the functional outcome of AIS patients.

Disclosed is a novel CT denoising method using deep learning to boost the image signal-to-noise ratio for improved disease detection in patients with acute ischemic stroke (AIS). This method reduced the original CT image noise significantly better than BM3D, with SNR improvements in GM, WM, and DG by 2.47×, 2.83×, and 2.64× respectively and CNR improvements in DG / WM and GM / WM by 2.30× and 2.16× respectively. Scans denoised by the proposed model are shown to be visually clearer with preserved anatomy. The disclosed deep learning model significantly reduces image noise and improves signal-to-noise and contrast-to-noise ratios in 380 unseen head NCCT cases.